More importantly, the combination of anti-CTLA-4 and anti-PD-1/PD-L1 showed stronger anti-tumour activity than monotherapy (Ott et al., 2013; Wolchok et al., 2013; Larkin et al., 2015). Here, PDCD1 is linked to neoplasm.